Where human focus meets scientific execution. The Parkinson’s Precision Principle: Clinical programs built around people, not just protocols Parkinson’s disease (PD) research is fueled by an extraordinary community, led by those living with the disease and navigating its uncertainty every day. People with Parkinson’s disease choose to enroll in clinical
Early in clinical development, it’s easy to focus on what’s directly in front of you. After all, your goal is to hit milestones, generate strong data, and keep the program moving forward. What’s easier to forget in the midst of it all is that regulators start forming an opinion about
Parkinson’s disease trials are not only complex studies, but they are long, personal commitments for every patient, caregiver, and investigator involved. That raises the question: Is your study truly structured to support them? Parkinson’s trials challenge every operational decision your team makes—about site strategy, timelines, data consistency, patient experience, and
Events Look for Rho at these conferences and tradeshows 12 events found. Events Events Search and Views Navigation Search Enter Keyword. Search for Events by Keyword. Find Events Event Views Navigation List List Month Today Upcoming Upcoming Select date. May 2026 Sun 24 7th World Parkinson Congress May 24 –
How confident are you that your acute pain study will behave the way it’s designed to? In planning sessions, most protocols look neat and predictable. But the moment your study meets actual patient, site, and clinical realities, small shifts can quickly change how clearly treatment benefit can be demonstrated. So,
Coordinated teamwork, consistently executed. The Acute Pain Imperative: Cohesive execution is critical Acute pain studies are operationally unforgiving, burdened with tight windows, subjective endpoints, and no margin for missed data. Short exposure periods, time-sensitive assessments, and rescue medication create conditions where even small inconsistencies can quickly impact data quality and
Early clinical decisions shape regulatory risk and the path to approval Assumptions about study design and real-world execution don’t stay contained to a single milestone. Over time, they influence how clearly treatment benefit can be demonstrated…and how credible the overall approval story ultimately feels to regulators. One of the
